Abstract
N-acetyl larazotide (larazotide acetate) is an investigational octapeptide that modulates tight junctions (TJs) in intestinal epithelial cells, offering therapeutic potential in conditions characterized by increased intestinal permeability, such as celiac disease, inflammatory bowel disease, and acute pancreatitis. This article reviews larazotide’s mechanisms of action, including its role in TJ assembly, actin cytoskeleton rearrangement, and epithelial barrier restoration, based on in vitro and in vivo studies. The peptide’s efficacy in enhancing barrier integrity and reducing pathological permeability is discussed, highlighting its promise as a targeted treatment for gastrointestinal disorders.
Introduction
The intestinal epithelium serves as a critical barrier, regulating the selective permeability of nutrients while preventing the translocation of harmful luminal contents. Tight junctions (TJs) are integral to this barrier function, and their disruption is implicated in various gastrointestinal diseases. Larazotide acetate, a synthetic peptide derived from the zonula occludens toxin (Zot) of Vibrio cholerae, has emerged as a potential therapeutic agent that modulates TJs to restore barrier integrity. This review examines the effects of larazotide on intestinal epithelial cells and its therapeutic implications.
Mechanisms of Action
Tight Junction Assembly and Actin Cytoskeleton Rearrangement
Larazotide acetate promotes the assembly of TJs by enhancing the localization of TJ proteins such as zonula occludens-1 (ZO-1), occludin, and claudins at the cell membrane. In vitro studies using MDCK and Caco-2 cells demonstrated that larazotide facilitates the redistribution of these proteins to the junctional complex, thereby strengthening the epithelial barrier. Additionally, larazotide induces actin cytoskeleton rearrangement, which is essential for TJ integrity and function .
Inhibition of TJ Disruption by Gliadin and Cytokines
In celiac disease, gliadin peptides and pro-inflammatory cytokines disrupt TJs, leading to increased intestinal permeability. Larazotide acetate counteracts this effect by inhibiting the redistribution of TJ proteins and actin filaments induced by gliadin and cytokines. It prevents the decrease in transepithelial electrical resistance (TEER) and the opening of TJs, thereby maintaining barrier function .
Restoration of Barrier Function in Ischemic Injury
Larazotide has been shown to facilitate the recovery of TJ integrity following ischemic injury. In porcine models of jejunal ischemia, larazotide treatment enhanced TEER and reduced paracellular flux of lipopolysaccharides. The peptide promoted the localization of claudin-4, a sealing TJ protein, at the epithelial junctions, contributing to barrier restoration .
Therapeutic Applications
Celiac Disease
Clinical trials have evaluated larazotide acetate as an adjunct therapy for celiac disease. The peptide’s ability to prevent gliadin-induced TJ disruption suggests its potential to reduce gluten-induced symptoms in patients adhering to a gluten-free diet. Larazotide’s gut-restricted action minimizes systemic exposure, making it a promising candidate for long-term management of celiac disease .
Inflammatory Bowel Disease and Acute Pancreatitis
Beyond celiac disease, larazotide’s TJ-modulating effects have been explored in other inflammatory conditions. In rat models of acute pancreatitis, larazotide administration reduced intestinal permeability, bacterial translocation, and mucosal damage. These findings indicate its potential in mitigating systemic inflammatory responses associated with intestinal barrier dysfunction .
Radiation-Induced Enteropathy
Radiation therapy can compromise intestinal barrier function, leading to enteropathy. Larazotide treatment in irradiated mice preserved TJ protein expression and localization, reduced bacterial translocation, and improved histological outcomes. These results suggest that larazotide may protect against radiation-induced intestinal damage by maintaining epithelial integrity .
Conclusion
Larazotide acetate exhibits a multifaceted mechanism of action that reinforces intestinal epithelial barrier function by promoting TJ assembly and preventing disruption by pathogenic stimuli. Its efficacy in preclinical and clinical studies underscores its therapeutic potential in diseases characterized by increased intestinal permeability. Further research is warranted to fully elucidate its benefits and optimize its clinical applications.
References:
- Gopalakrishnan, S., et al. (2012). Larazotide acetate promotes tight junction assembly in epithelial cells. PubMed. https://pubmed.ncbi.nlm.nih.gov/22401910/
- Gopalakrishnan, S., et al. (2012). Larazotide acetate regulates epithelial tight junctions in vitro and in vivo. PubMed. https://pubmed.ncbi.nlm.nih.gov/22401908/
- Khaleghi, S., et al. (2016). The potential utility of tight junction regulation in celiac disease: focus on larazotide acetate. Therapeutic Advances in Gastroenterology. https://journals.sagepub.com/doi/full/10.1177/1756283X15616576
- Turner, J.R., et al. (2021). Larazotide acetate: a pharmacological peptide approach to tight junction regulation. American Journal of Physiology-Gastrointestinal and Liver Physiology. https://journals.physiology.org/doi/full/10.1152/ajpgi.00386.2020
- Demir, E., et al. (2024). Ameliorative effects of larazotide acetate on intestinal permeability and bacterial translocation in acute pancreatitis model in rats. PubMed. https://pubmed.ncbi.nlm.nih.gov/38441784/
- Lee, S.H., et al. (2021). Larazotide acetate induces recovery of ischemia-injured porcine jejunum via repair of tight junctions. PubMed. https://pubmed.ncbi.nlm.nih.gov/33886649/
- Lee, S.H., et al. (2021). Larazotide acetate induces recovery of ischemia-injured porcine jejunum via repair of tight junctions. PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC8061941/
- Lee, S.H., et al. (2021). Larazotide acetate induces recovery of ischemia-injured porcine jejunum via repair of tight junctions. PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC8061941/
- Lee, S.H., et al. (2021). Larazotide acetate induces recovery of ischemia-injured porcine jejunum via repair of tight junctions. PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC8061941/
- Lee, S.H., et al. (2021). Larazotide acetate induces recovery of ischemia-injured porcine jejunum via repair of tight junctions. PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC8061941/
